EP Patent

EP0920864A1 — Combination therapy including a specific beta-3 agonist and an anorectic agent

Assigned to Pfizer Products Inc · Expires 1999-06-09 · 27y expired

What this patent protects

This invention relates to pharmaceutical compositions and methods which have utility in treating obesity in animals and particularly in humans. The invention is particularly directed to such compositions which comprise a mixture of a compound which modifies eating behavior and (4…

USPTO Abstract

This invention relates to pharmaceutical compositions and methods which have utility in treating obesity in animals and particularly in humans. The invention is particularly directed to such compositions which comprise a mixture of a compound which modifies eating behavior and (4-(2-(2-(6-aminopyridin-3-yl)-2(R)-hydroxyethylamino)ethoxy)phenyl)acetic acid, which is the compound of Formula I:

Drugs covered by this patent

Patent Metadata

Patent number
EP0920864A1
Jurisdiction
EP
Classification
Expires
1999-06-09
Drug substance claim
No
Drug product claim
No
Assignee
Pfizer Products Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.